Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.

Simtriyo (centanafadine)

The FDA approved Simtriyo (centanafadine) on July 24, 2026 to treat attention-deficit hyperactivity disorder.

Brand name: Simtriyo
Generic name: centanafadine
FDA approval date: July 24, 2026
Approved use (FDA wording): To treat attention-deficit hyperactivity disorder
Category on this site: Rare & genetic

Official sources

FDA novel drug approvals list

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.